Skip to main content
SpringerLink
Log in
Book cover

Sepsis und MODS pp 511–524Cite as

Heparin, Antithrombin, Gewebethromboplastin-Inhibitor und aktiviertes Protein C: Stellenwert für die Therapie der schweren Sepsis?

  • Chapter

  • 705 Accesses

This is a preview of subscription content, log in via an institution.

eBook
USD   4.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abraham E, Reinhart K, Svoboda P et al. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled single-blind, dose escalation study. Crit Care Med 29: 2081–2089

    PubMed  CAS  Google Scholar 

  2. Abraham E, Reinhart K, Opal S et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290/2: 238–247

    Article  Google Scholar 

  3. Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301–1308

    Google Scholar 

  4. Angus DC, Laterrre P-F, Helterbrand J, Ball D, Garg R, Bernard GR (2003) The effect of drotrecogin α (activated) on long-term survival after severe sepsis. Chest 122(Suppl): S144

    Google Scholar 

  5. Annane D, Sebile V, Charpentier C et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862–871

    Article  PubMed  CAS  Google Scholar 

  6. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma carboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271: 16603–16608

    PubMed  CAS  Google Scholar 

  7. Barie PS (2002) Drotrecogin α (activated) has a favorable benefit/risk profile in surgical patients with severe sepsis. Crit Care Med 30(Suppl 12): A102

    Google Scholar 

  8. Barnes PJ, Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066–1071

    Article  PubMed  CAS  Google Scholar 

  9. Bellomo R, Farmer M, Wright C, Parkin G, Boyce N (1995) Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: clinical experience and comparison with conventional dialysis. Blood Purif 13: 246–254

    PubMed  CAS  Google Scholar 

  10. Bernard G (2002) The International Sepsis Forum’s controversies in sepsis: corticosteroids should not be routinely used to treat septic shock. Crit Care 6: 384–386

    Article  PubMed  Google Scholar 

  11. Bernard GR, Ely EW, Wright TJ et al. (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051–2059

    PubMed  CAS  Google Scholar 

  12. Bernard GR, Macias WL, Vincent JL (2002) Drotrecogin α (activated) cumulative safety update. Chest 122(Suppl): S141

    Google Scholar 

  13. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709

    Article  PubMed  CAS  Google Scholar 

  14. Bick RL (2002) Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis and management: guidelines for care. Clin Appl Thromb Hemost 8: 1–31

    PubMed  CAS  Google Scholar 

  15. Bick RL, Arum B, Frenkel EP (1999) Disseminated intravascular coagulation. Clinical and pathophysiological mechanisms and manifestations. Haemostasis 29: 111–134

    PubMed  CAS  Google Scholar 

  16. Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81–89

    Article  PubMed  CAS  Google Scholar 

  17. Chiron EC (2002) Chiron announces results of phase III study of tifacogin in severe sepsis. Chiron, Emeryville, USA, Internet Communication, accessed September 6

    Google Scholar 

  18. Corrigan JJ, Ray WL, May N (1968) Changes in the blood coagulation system associated with septicemia. N Engl J Med 279: 851–856

    Article  PubMed  Google Scholar 

  19. Creasey AA, Reinhart K (2001) Tisue factor pathway inhibitor activity in severe sepsis. Crit Care Med 29(Suppl): S126–S129

    PubMed  CAS  Google Scholar 

  20. Jonge E de, Levi M, Stoutenbeek CP, van Deventer SJ (1998) Current drug treatment strategies for disseminated intravascular coagulation. Drugs 55: 767–777

    PubMed  Google Scholar 

  21. Eisele B, Lamy M (1998) Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 24: 71–80

    PubMed  CAS  Google Scholar 

  22. Ely EW, Baker AM, Dunagan DP et al. (1996) Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 335: 1864–1869

    Article  PubMed  CAS  Google Scholar 

  23. Esmon C (2000) The protein pathway. Crit Care Med 28(Suppl): S44–S48

    PubMed  CAS  Google Scholar 

  24. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25: 537–541

    PubMed  CAS  Google Scholar 

  25. Faust SN, Levin M, Harrison OB et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408–416

    Article  PubMed  CAS  Google Scholar 

  26. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882–888

    PubMed  CAS  Google Scholar 

  27. Fourrier F, Jourdain M, Tournoys A (2000) Clinical trial results with antithrombin III in sepsis. Crit Care Med 28(Suppl): S38–S43

    PubMed  CAS  Google Scholar 

  28. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O (2002) Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 30: 1729–1734

    PubMed  CAS  Google Scholar 

  29. Gardlund B (2000) Antithrombin therapy of no value in sepsis according to a large clinical trial. Lakartidningen 99: 1456–1460

    Google Scholar 

  30. Grinnell BW, Joyce D (2001) Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29(Suppl): S53–S60

    PubMed  CAS  Google Scholar 

  31. Gross PL, Aird WC (2000) The endothelium and thrombosis. Semin Thromb Hemost 26: 463–478

    Article  PubMed  CAS  Google Scholar 

  32. Hancock WW, Grey ST, Hau L et al. (1995) Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60: 1525–1532

    PubMed  CAS  Google Scholar 

  33. Hesselvik JF, Malm J, Dahlback B, Blomback M (1991) Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 65: 126–129

    PubMed  CAS  Google Scholar 

  34. Iba T, Kidokoro A, Yagi Y (1991) The role of the endothelium in changes in procoagulant activity in sepsis. Thromb Haemost 65: 126–129

    Google Scholar 

  35. Iba T, Yagi Y, Kidokoro A (1998) Protective effects of antithrombin III on organ dysfunction induced by the continuous infusion of endotoxin in rats. J Jpn Assoc Acute Med 9: 45–52

    Google Scholar 

  36. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M (1998) Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 10: 90–96

    PubMed  CAS  Google Scholar 

  37. Jimenez MF, Marshall JC (2001) Source control in the management of sepsis. Intensive Care Med 27(Suppl 1): S49–S62

    PubMed  Google Scholar 

  38. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11.199–11.203

    Article  Google Scholar 

  39. a Kujath P, Bouchard R, Heinze I, Thees C, Putensen C (2003) Aktiviertes Protein C, Antithrombin, Heparin und Gewebethromboplastininhibitor: Neue Algorithmen für die Therapie der schweren Sepsis? Intensiv Notfallbeh 28: 44–54

    Google Scholar 

  40. Lasch HG, Krecke H-J, Rodriguez-Erdmann F, Sessner HH, Schütterle G (1961) Verbrauchskoagulopathien (Pathogenese und Therapie). Folia Haematol 6: 325–330

    CAS  Google Scholar 

  41. Laterre P-F, Levy H, Bal D, Helterbrand J, Angus DC (2002) The effects of drotrecogin α (activated) on hospital mortality, length of stay, and discharge location. Chest 122(Suppl): S143

    Google Scholar 

  42. Levi M, van der Poll PT, ten Cate H, van Deventer SJ (1997) The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 27: 3–9

    Article  PubMed  CAS  Google Scholar 

  43. Marik PE, Zaloga GP (2001) Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 29: 2264–2270

    PubMed  CAS  Google Scholar 

  44. Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P (1994) Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis 24: 36–48

    PubMed  CAS  Google Scholar 

  45. Moalli R, Doyle JM, Tahhan HR, Hasan FM, Braman SS, Saldeen T (1989) Fibrinolysis in critically ill patients. Am Rev Respir Dis 140: 287–293

    PubMed  CAS  Google Scholar 

  46. Morris P, Garber G, Laterre P-F, Levy H (2001) Drotrecogin α (activated) reduced the number of deaths attributed to cardiovascular and pulmonary organ failure in patients with severe sepsis. Crit Care Med 29(Suppl): A11

    Google Scholar 

  47. Müller-Berghaus G, ten Cate H, Levi M (1999) Disseminated intravascular coagulation: clinical spectrum, and established as well as new diagnostic approaches. Thromb Haemost 82: 706–712

    PubMed  Google Scholar 

  48. Muller FM, Ehrenthal W, Hafner G, Schranz D (1996) Purpura fulminans in severe congenital protein C deficieny: monitoring of treatment with protein C concentrate. Eur J Pediatr 155: 20–25

    PubMed  CAS  Google Scholar 

  49. Okajima K, Uchiba M (1998) The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 24: 27–32

    Article  PubMed  CAS  Google Scholar 

  50. Pettila V, Hyminen M, Takkunen O, Kuusela P, Valtonen M (2002) Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 28: 1220–1225

    PubMed  Google Scholar 

  51. Reinhart K, Bayer O, Brunkhorst F, Meisner M (2002) Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30(Suppl): S302–S312

    PubMed  CAS  Google Scholar 

  52. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296: 1880–1882

    Article  PubMed  CAS  Google Scholar 

  53. Rintala E, Kauppila M, Seppala OP et al. (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28: 2373–2378

    PubMed  CAS  Google Scholar 

  54. Rivers E, Nguyen B, Havstad S (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377

    Article  PubMed  CAS  Google Scholar 

  55. Scherer RU, Pulletz S, Ziemer S, Peters J (2001) Antithrombin-(AT)Wirkung: Experimentelle und klinische Ergebnisse. Anästhesiol Intensivmed Notfallmed Schmerzther 36: 628–639

    PubMed  CAS  Google Scholar 

  56. Smith OP, White B (1999) Infectious purpura fulminans: diagnosis and treatment. Br J Haematol 104: 202–207

    Article  PubMed  CAS  Google Scholar 

  57. Tylor FB Jr (1994) The inflammatoy-coagulant axis in the host response to Gram-negative sepsis: regulatory roles of proteins and inhibitors of tissue factor. New Horiz 2: 555–565

    Google Scholar 

  58. Van den Berghe BG, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359–1367

    PubMed  Google Scholar 

  59. Warren BL, A Eid, Singer P et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869–1878

    PubMed  CAS  Google Scholar 

  60. Yan SB, Dhainaut JF (2001) Activated protein C vs. protein C in severe sepsis. Crit Care Med 29(Suppl): S69–S74

    PubMed  CAS  Google Scholar 

  61. Yan SB, Helerbrand JD, Hartman DL, Wright TJ, Bernard GR (2001) Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120: 915–922

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Anästhesiologie und Spezielle Intensivmedizin, Universitätsklinikum Bonn, Siegmund-Freud-Str. 25, 53105, Bonn

    C. Putensen (Prof. Dr.), I. Heinze (Dr.) & C. Thees

  2. Klinik für Chirurgie, Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck

    P. Kujath (Prof. Dr.) & R. Bouchard

Authors
  1. C. Putensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Kujath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Bouchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Heinze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Thees
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik und Poliklinik für Innere Medizin III Klinikum Kröllwitz der, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Str. 40, 06097, Halle/Saale

    Karl Werdan  & Ursula Müller-Werdan  & 

  2. Städtisches Krankenhaus Hildesheim, Weinberg 1, 31134, Hildesheim

    Hans-Peter Schuster

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Putensen, C., Kujath, P., Bouchard, R., Heinze, I., Thees, C. (2005). Heparin, Antithrombin, Gewebethromboplastin-Inhibitor und aktiviertes Protein C: Stellenwert für die Therapie der schweren Sepsis?. In: Werdan, K., Schuster, HP., Müller-Werdan, U. (eds) Sepsis und MODS. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26587-2_21

Download citation

  • DOI: https://doi.org/10.1007/3-540-26587-2_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00004-4

  • Online ISBN: 978-3-540-26587-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation